Ceftobiprole Medocaril: A New Fifth-Generation Cephalosporin

Document Type

Article

Publication Date

12-7-2024

Publication Title

The Annals of pharmacotherapy

Abstract

OBJECTIVE: The objective was to review the pharmacology, efficacy, and safety of intravenous ceftobiprole in the treatment of bloodstream infections, acute bacterial skin and skin structure infections (ABSSSIs), community-acquired pneumonia (CAP), and hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP).

DATA SOURCES: PubMed and ClinicalTrials.gov were searched using the following terms: ceftobiprole, ceftobiprole medocaril, ceftobiprole medocaril sodium, Zevtera, and BAL5788.

STUDY SELECTION AND DATA EXTRACTION: Articles published in English between January 1985 and August 15, 2024, related to pharmacology, safety, efficacy, and clinical trials were reviewed.

DATA SYNTHESIS: Ceftobiprole has shown similar efficacy to comparator antibiotics in CAP, ABSSSIs, and bloodstream infections. Overall treatment success in patients with bacteremia was 69.8% and 68.7%; 91.3% and 88.1% with ABSSSIs and 86.6% and 87.4% with CAP in ceftobiprole and comparator groups, respectively. Finally, in the management of HAP and VAP, ceftobiprole was inferior in the VAP population. Ceftobiprole had a favorable safety profile with gastrointestinal adverse effects occurring more frequently than comparators.

RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE IN COMPARISON TO EXISTING DRUGS: Clinicians have limited options to treat multidrug-resistant infections. Ceftobiprole has demonstrated efficacy against causative pathogens in specific infections including methicillin-resistant Staphylococcus aureus bacteremia (SAB), ABSSSI, and CAP and may be considered a viable alternative. However, ceftobiprole's impact on HAP, VAP, and febrile neutropenia needs to be further delineated.

CONCLUSION: Ceftobiprole's broad-spectrum activity makes it a viable option for treating patients hospitalized with CAP, ABSSSI, and SAB. Further studies are needed in severely ill HAP or VAP, febrile neutropenia, and pediatric patients.

Medical Subject Headings

Humans; Cephalosporins/adverse effects/therapeutic use/pharmacology/administration &; dosage; Anti-Bacterial Agents/adverse effects/therapeutic; use/pharmacology/administration & dosage; Community-Acquired Infections/drug therapy; Cross Infection/drug therapy; Pneumonia; Ventilator-Associated/drug therapy; Bacteremia/drug therapy; Skin Diseases; Bacterial/drug therapy; Bal5788; Bal9141; ceftobiprole; ceftobiprole medocaril; ceftobiprole medocaril sodium

PubMed ID

39644134

ePublication

ePub ahead of print

Volume

59

Issue

7

First Page

657

Last Page

665

Find It @ Sladen

Share

COinS